Key Takeaway: Cognition Therapeutics has released findings from the Phase 2 SEQUEL study of CT1812, which targets Mild-to-Moderate Alzheimer's Disease. The published EEG results indicate potential benefits of the treatment. This research contributes to the ongoing efforts to find effective therapies for Alzheimer's patients.
Price reaction · baseline $0.7498 (2024-08-21 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
+1.2%
day 1
-1.6%
day 3 · peak
-6.9%
Market Sentiment Analysis
POSITIVE FACTORS
Cognition Therapeutics has published promising EEG findings.
The study focuses on a treatment for Mild-to-Moderate Alzheimer's Disease.
CT1812 shows potential in addressing Alzheimer's symptoms.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Frequently Asked Questions
What is the SEQUEL study?
The SEQUEL study is a Phase 2 clinical trial investigating CT1812 for Alzheimer's Disease.
What are the findings of the EEG study?
Cognition Therapeutics published EEG findings indicating potential benefits of CT1812.